Monroe1
1 주 전
Get out or get short while you can. https://dailynewscycle.com/rfk-jr-unveils-plan-to-curb-big-pharmas-influence-on-u-s-healthcare/
Kennedy noted that pharmaceutical companies provide a significant portion of revenue for major news networks, effectively controlling much of the information disseminated to the public.
“75% of the revenues for those evening news shows, or, you know, Anderson Cooper, is coming from Pfizer and other pharmaceutical companies,” he explained.
Kennedy argues that this advertising is a major factor driving up healthcare costs, contributing to America’s status as one of the most expensive and least effective healthcare systems in the world.
“The CDC has a vaccine safety database that’s kept in a lockbox like Fort Knox,” Kennedy said. “I’ll open up that database on day one.”
Kennedy also plans to take legal action against prominent medical journals, accusing them of colluding with pharmaceutical companies to mislead the public. He specifically called out The New England Journal of Medicine, The Lancet, and JAMA, alleging that they have become tools of a “racketeering syndicate.”
“You guys are collaborating with the pharmaceutical industry to lie to the American public about the efficacy and safety of these products,” Kennedy said. “We are going to sue you both civilly for damages and criminally for fraud.”
Monroe1
2 주 전
They should be shaking scared about now. "As for the industry’s initial reactions on the innovation front, the Pharmaceutical Research and Manufacturers of America (PhRMA) wants to “work with his administration to further strengthen our innovation ecosystem that enables the United States to lead the world in medicine development,” CEO Stephen Ubl said in a statement. “New medicines are transforming our ability to prevent, treat, and cure deadly disease, improving patient lives and helping to avoid the most expensive parts of our health care system.”
"“We are committed to working with the Trump administration and the new Congress to make our health care system work better for patients while preserving our unique ecosystem that enables greater innovation and lower costs for patients,” Ubl said.
Of course, a recent twist in Trump’s later campaign days was the introduction of Robert F. Kennedy Jr. as a prospect to head up healthcare. Kennedy, who scrapped his own campaign for the presidency in August, is widely known for his anti-vaccine rhetoric and conspiracies and was even temporarily banned from Instagram in 2021 for spreading misinformation about COVID-19 vaccines. At a rally in New York, Trump pledged to, if elected, allow Kennedy to “go wild on health” as well as “the medicines.”
Kennedy later delivered a grim message to the FDA on X, formerly Twitter, warning those who “work for the FDA and are part of this corrupt system” to “1. Preserve your records, and 2. Pack your bags.” Today, Fierce Biopharma
Monroe1
3 주 전
Analysts Adjust Pfizer Projections, Citing Uncertain Q4 Outlook
Nauman Khan
Mon, November 4, 2024 at 10:11 a.m. CST 1 min read
In This Article:
PFE
-0.96%
Leerink Partners has lowered its fourth-quarter 2024 EPS estimate for New York-based pharmaceutical giant Pfizer (PFE, Financial), adopting a conservative stance for the quarter. The firm reduced its EPS forecast from $0.79 to $0.63. Despite this adjustment, Pfizer recently outperformed expectations in Q3, reporting an EPS of $1.06 compared to the market consensus of just $0.64. This surge in performance was bolstered by an exceptional increase in revenue, which reached $17.70 billion, significantly surpassing market expectations of $14.92 billion.
Warning! GuruFocus has detected 8 Warning Signs with PFE.
This performance has led to year-over-year revenue growth of 31.2%, indicating that Pfizer has a strong market base despite its worst financial outlook. However, Leerink downgraded P and forecasted concerns about the firm's future earning capabilities, which puts a more cautious view than the current market. The outlook is a moderate buy with a target price of $33.58.
The broader analyst community has given some ratings upgrades, and despite a recent cut, they highlight a cautiously optimistic scenario. Exclusive: Citigroup and Sanford C. Bernstein have retained neutral calls as the industry dynamics play out. UBS and Wells Fargo have marginally lifted their target prices following their steady market journey.
Businesspeople appear uncertain, and something has changed as Pfizer's shares dropped to $28.08; however, institutional buying persists. The hedge funds and financial industry players, such as LGT Group Foundation and Creative Planning, have continued to flock significant funds toward Pfizer for further investment due to the organization's affluent prospects in the biopharmaceutical industry.
Pfizer is well aware of the current market and regulatory systems worldwide, and yet the world looks at this company's financial status against the backdrop of constant emerging health crises and competitors.
This article first appeared on GuruFocus.
Hot Features
프리미엄
실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
IHuser
2 일 전
Vexari
2 일 전
Lime Time
1 주 전
DewDiligence
3 주 전
